title: Probing the interaction of SR141716A with the CB1 receptor.
abstract: SR141716A binds selectively to the brain cannabinoid (CB1) receptor and exhibits a potent inverse agonist/antagonist activity. Although SR141716A, also known as rimonabant, has been withdrawn from the market due to severe side effects, there remains interest in some of its many potential medical applications. Consequently, it is imperative to understand the mechanism by which SR141716A exerts its inverse agonist activity. As a result of using an approach combining mutagenesis and molecular dynamics simulations, we determined the binding mode of SR141716A. We found from the simulation of the CB1-SR141716A complex that SR141716A projects toward TM5 to interact tightly with the major binding pocket, replacing the coordinated water molecules, and secures the Trp-356(6.48) rotameric switch in the inactive state to promote the formation of an extensive water-mediated H-bonding network to the highly conserved SLAXAD and NPXXY motifs in TM2/TM7. We identify for the first time the involvement of the minor binding pocket formed by TM2/TM3/TM7 for SR141716A binding, which complements the major binding pocket formed by TM3/TM5/TM6. Simulation of the F174(2.61)A mutant CB1-SR141716A complex demonstrates the perturbation of TM2 that attenuates SR141716A binding indirectly. These results suggest SR141716A exerts inverse agonist activity through the stabilization of both TM2 and TM5, securing the Trp-356(6.48) rotameric switch and restraining it from activation.
authors.affiliation: J. L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina 27707, USA. jyshim@nccu.edu
authors.forename: Joong-Youn
authors.initials: JY
authors.lastname: Shim
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Bertalovitz
authors.forename: Debra A
authors.initials: DA
authors.lastname: Kendall
mesh_terms: D000595:Amino Acid Sequence; D001665:Binding Sites; D063387:Cannabinoid Receptor Antagonists / Q000737:chemistry; D002462:Cell Membrane / Q000378:metabolism; D002784:Cholesterol / Q000737:chemistry; D006801:Humans; D006860:Hydrogen Bonding; D008024:Ligands; D056004:Molecular Dynamics Simulation; D008969:Molecular Sequence Data; D009154:Mutation; D010880:Piperidines / Q000737:chemistry*; D011485:Protein Binding; D011720:Pyrazoles / Q000737:chemistry*; D043884:Receptor, Cannabinoid, CB1 / Q000737:chemistry*; D043882:Receptors, Cannabinoid / Q000737:chemistry; D043562:Receptors, G-Protein-Coupled; D000077285:Rimonabant; D015398:Signal Transduction
chemical_list: D063387:Cannabinoid Receptor Antagonists; D008024:Ligands; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled; D002784:Cholesterol; D000077285:Rimonabant